GLPBio

Cell Cycle/Checkpoint

Cell Cycle/Checkpoint

Cell Cycle

Cells undergo a complex cycle of growth and division that is referred to as the cell cycle. The cell cycle consists of four phases, G1 (GAP 1), S (synthesis), G2 (GAP 2) and M (mitosis). DNA replication occurs during S phase. When cells stop dividing temporarily or indefinitely, they enter a quiescent state called G0.

Research Areas

Products Related to Cell Cycle/Checkpoint(1447)

  • GC74159 structure
    GC74159MK-0731
    CAS: 845256-65-7
    Purity: >99.00%

    MK-0731は選択性、非競争性、および変異型アクチュエーター紡錘体タンパク質（KSP）阻害剤であり、IC 50は2.2 nM、pKaは7.6である。

  • GC74279 structure
    GC74279Ganoderic acid T-Q
    CAS: 112430-66-7
    Purity: >99.00%

    Ganoderic acid T-Q (ganodermic acid t-q)(化合物1)は、霊芝に含まれる天然物である。

  • GC74280 structure
    GC74280Dihydrobaicalein
    CAS: 35683-17-1
    Purity: >99.00%

    DihydrobaicaleinはPLK 1阻害剤であり、IC 50は6.3μMである。

  • GC74316 structure
    GC74316ATR kinase substrate peptide
    Purity: >99.00%

    ATR kinase substrate peptide (compound 45)は、atr (ataxia telangiectasia and rad3 related)プロテインキナーゼ(ki =6 nm)の強力かつ選択的阻害剤です。

  • GC74326 structure
    GC74326MPSD TFA
    Purity: >98.00%

    MPSD TFA（MARCKS-ED TFA）は、MPSDのTFA塩形態である。

  • GC74519 structure
    GC74519Cantuzumab ravtansine
    CAS: 868747-45-9
    Purity: >98.00%

    Cantuzumab ravtansine（IMGN 242、huC 242-DM 4）はADCであり、ジチオ結合を介してDM 4（DM 4）に共有結合するヒト化モノクローナル抗体huC 242である。

  • GC74533 structure
    GC74533Tusamitamab ravtansine
    CAS: 2254086-60-5
    Purity: >99.00%

    Tusamitamab ravtansine（SAR-408701）はCEACAM 5を発現する腫瘍細胞に対する標的ADCであり、ヒト化抗CEACAM 5モノクローナル抗体から構成され、この抗体は切断可能な継ぎ手を介して強力な細胞毒性剤メデンチン類DM 4と共有結合している。

  • GC74600 structure
    GC74600Cofetuzumab pelidotin
    CAS: 1869937-48-3
    Purity: >99.00%

    Cofetuzumab pelidotin（PF-06647020）は、ヒト化抗PTK 7モノクローナル抗体を含むPTK 7を標的とするADCであり、バリン-シトルリン（vc）に基づく切断可能な継手を介してauristatinマイクロチューブ阻害剤有効荷重auristain-0101に接続されている。

  • GC78758 structure
    GC78758Mal-Val-Lys-PAB-MMAE TFA
    Purity: >98.00%

    Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC.

  • GC78762 structure
    GC78762Trastuzumab-DM4
    Purity: >98%

    Trastuzumab -DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab with DM4 (sulfo-SPDB-DM4) via a cleavable linker.

  • GC78763 structure
    GC78763ADC Control Human IgG1-sulfo-SPDB-DM4
    Purity: >98.00%

    ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) and can inhibit tubulin polymerization.

  • GC78764 structure
    GC78764Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
    CAS: 3103526-19-5
    Purity: >97.50%

    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

  • GC78765 structure
    GC78765LP-6 TFA
    CAS: 1629741-09-8
    Purity: >98.00%

    LP-6 TFA is a Drug-Linker Conjugate for ADC, and can be used for synthesis of ADCs.

  • GC78766 structure
    GC78766N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan)
    Purity: >98.00%

    N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition.

  • GC78767 structure
    GC78767N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
    Purity: >98.00%

    N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition.

  • GC78791 structure
    GC78791AMG-172
    Purity: >98%

    AMG-172 is an antibody-drug conjugate ( ADC ) composed of a fully human IgG1 monoclonal anti- CD27L antibody conjugated to DM1 via the non-cleavable linker MCC.

  • GC78798 structure
    GC78798NN3201
    Purity: >99.00%

    NN3201 is a c-Kit -targeting antibody-drug conjugate ( ADC ) with high affinity ( K D = 0.19 pM).

  • GC78956 structure
    GC78956MYCMI-7 hydrobromide
    CAS: 102537-38-2
    Purity: >95.00%

    MYCMI-7 hydrobromide is a potent and selective MYC/MYCN inhibitor, with a K d of 4 μM for MYC and an IC 50 of 10 μM for topoisomerase IIα ( Topoisomerase II α ).

  • GC78959 structure
    GC78959c-Myc NLS TFA
    Purity: >98.00%

    c-Myc NLS TFA is a non-canonical nuclear localization signal (NLS) derived from the oncoprotein c-Myc, with the sequence PAAKRVKLD and containing 3 basic amino acids.

  • GC78960 structure
    GC78960DL78
    CAS: 132993-79-4
    Purity: >99.00%

    DL78 is an effective anti-mitotic agent.

  • GC78995 structure
    GC78995ZY39
    CAS: 2999673-51-5
    Purity: >99.50%

    ZY39 is a Sa ClpP agonist.

  • GC79000 structure
    GC79000Q901 TFA
    Purity: >98.50%

    Q901 (CDK7-IN-21) TFA is a selective and potent CDK7 inhibitor with an IC 50 of 10 nM.

  • GC79004 structure
    GC79004PMV6-PEG4-BI2536
    Purity: >98.00%

    PMV6-PEG4-BI2536 is an RIPTAC-like bifunctional molecule that promotes the formation of the p53 Y 220C -PLK1 ternary complex ( EC 50 = 1.4 μM).

  • GC79008 structure
    GC79008WY165
    Purity: >99.00%

    WY165 is a bifunctional molecule comprising TR79, an activator of the mitochondrial protease complex caseinolytic protease P ( ClpP ), linked to desthiobiotin.